14References

Publication Details

1.
Abramson EL, Barron Y, Quaresimo J, Kaushal R. Electronic prescribing within an electronic health record reduces ambulatory prescribing errors. Joint Commission Journal on Quality and Patient Safety. 2011;37(10):470–478. [PubMed: 22013821]
2.
Academy of Medical Royal Colleges. i-care: information, communication and technology in the NHS. London: Academy of Medical Royal Colleges; 2013.
3.
Agbabiaka TB, Savovic J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Safety. 2008;31(1):21–37. [PubMed: 18095744]
4.
Andri L, Falagiani P. Safety of celecoxib in patients with cutaneous reactions due to ASA-NSAIDs intolerance. Allergologia Et Immunopathologia. 2007;35(4):126–129. [PubMed: 17663920]
5.
Arimone Y, Bidault I, Dutertre JP, Gerardin M, Guy C, Haramburu F, et al. Updating the French method for the causality assessment of adverse drug reactions. Therapie. 2013;68(2):69–76. [PubMed: 23773347]
6.
Arnott J, Hesselgreaves H, Nunn AJ, Peak M, Pirmohamed M, Smyth RL, et al. Enhancing communication about paediatric medicines: lessons from a qualitative study of parents' experiences of their child's suspected adverse drug reaction. PloS One. 2012;7(10):e46022. [PMC free article: PMC3468607] [PubMed: 23071535]
7.
Asero R. Etoricoxib challenge in patients with chronic urticaria with NSAID intolerance. Clinical and Experimental Dermatology. 2007;32(6):661–663. [PubMed: 17953635]
8.
Bates DW, Leape LL, Cullen DJ, Laird N, Petersen LA, Teich JM, et al. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA. 1998;280(15):1311–1316. [PubMed: 9794308]
9.
Bates DW, Teich JM, Lee J, Seger D, Kuperman GJ, Ma'Luf N, et al. The impact of computerized physician order entry on medication error prevention. Journal of the American Medical Informatics Association. 1999;6(4):313–321. [PMC free article: PMC61372] [PubMed: 10428004]
10.
Bavbek S, Celik G, Ozer F, Mungan D, Misirligil Z. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib. Journal of Asthma. 2004;41(1):67–75. [PubMed: 15046380]
11.
Bavbek S, Dursun AB, Dursun E, Eryilmaz A, Misirligil Z. Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study. International Archives of Allergy and Immunology. 2007;142(1):64–69. [PubMed: 17016059]
12.
Begaud B, Evreux JC, Jouglard J, Lagier G. [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. Therapie. 1985;40(2):111–118. [PubMed: 4002188]
13.
Benahmed S, Picot MC, Hillaire-Buys D, Blayac JP, Dujols P, Demoly P. Comparison of pharmacovigilance algorithms in drug hypersensitivity reactions. European Journal of Clinical Pharmacology. 2005;61(7):537–541. [PubMed: 16021437]
14.
Benichou C, Danan G. Causality assessment in the European pharmaceutical industry: presentation of the preliminary results of a new method. Drug Information Journal. 1992;26:589–592.
15.
Benkhaial A, Kaltschmidt J, Weisshaar E, Diepgen TL, Haefeli WE. Prescribing errors in patients with documented drug allergies: comparison of ICD-10 coding and written patient notes. Pharmacy World and Science. 2009;31(4):464–472. [PubMed: 19412703]
16.
Blanc S, Leuenberger P, Berger JP, Brooke EM, Schelling JL. Judgments of trained observers on adverse drug reactions. Clinical Pharmacology and Therapeutics. 1979;25(5 Pt 1):493–498. [PubMed: 436353]
17.
Blanca M, Mayorga C, Torres MJ, Reche M, Moya MC, Rodriguez JL, et al. Clinical evaluation of Pharmacia CAP System RAST FEIA amoxicilloyl and benzylpenicilloyl in patients with penicillin allergy. Allergy. 2001;56(9):862–870. [PubMed: 11551251]
18.
Bousquet PJ, Demoly P, Romano A, Aberer W, Bircher A, Blanca M, et al. Pharmacovigilance of drug allergy and hypersensitivity using the ENDA-DAHD database and the GALEN platform. The Galenda project. Allergy. 2009;64(2):194–203. [PubMed: 19178398]
19.
Brown S, Black K, Mrochek S, Wood A, Bess T, Cobb J, et al. RADARx: Recognizing, Assessing, and Documenting Adverse Rx events. Proceedings. 2000:101–105. [PMC free article: PMC2243889] [PubMed: 11079853]
20.
Busto U, Naranjo CA, Sellers EM. Comparison of two recently published algorithms for assessing the probability of adverse drug reactions. British Journal of Clinical Pharmacology. 1982;13(2):223–227. [PMC free article: PMC1401984] [PubMed: 7059419]
21.
Butt TF, Cox AR, Lewis H, Ferner RE. Patient experiences of serious adverse drug reactions and their attitudes to medicines: a qualitative study of survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. Drug Safety. 2011;34(4):319–328. [PubMed: 21417504]
22.
Butt TF, Cox AR, Oyebode JR, Ferner RE. Internet accounts of serious adverse drug reactions: a study of experiences of Stevens-Johnson syndrome and toxic epidermal necrolysis. Drug Safety. 2012;35(12):1159–1170. [PubMed: 23058037]
23.
Caimmi S, Caimmi D, Bousquet PJ, Demoly P. How can we better classify NSAID hypersensitivity reactions?--validation from a large database. International Archives of Allergy and Immunology. 2012;159(3):306–312. [PubMed: 22739440]
24.
Castle WM. Assessment of causality in industrial settings. Drug Information Journal. 1984;18:297–302.
25.
Celik G, Pasaoglu G, Bavbek S, Abadoglu O, Dursun AB, Mungan D, et al. Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. Journal of Asthma. 2005;42(2):127–131. [PubMed: 15871445]
26.
Colanardi MC, Nettis E, Traetta P, Daprile C, Fitto C, Aloia AM, et al. Safety of parecoxib in patients with nonsteroidal anti-inflammatory drug-induced urticaria or angioedema. Annals of Allergy, Asthma and Immunology. 2008;100(1):82–85. [PubMed: 18254487]
27.
Colpaert K, Claus B, Somers A, Vandewoude K, Robays H, Decruyenaere J. Impact of computerized physician order entry on medication prescription errors in the intensive care unit: a controlled cross-sectional trial. Critical Care. 2006;10(1):R21. [PMC free article: PMC1550814] [PubMed: 16469126]
28.
Confino-Cohen R, Goldberg A. Safe full-dose one-step nabumetone challenge in patients with nonsteroidal anti-inflammatory drug hypersensitivity. Allergy and Asthma Proceedings. 2003;24(4):281–284. [PubMed: 12974196]
29.
Coombes ID, Stowasser DA, Reid C, Mitchell CA. Impact of a standard medication chart on prescribing errors: a before-and-after audit. Quality and Safety in Health Care. 2009;18(6):478–485. [PubMed: 19955461]
30.
Cornelli U. The phase IV monitoring studies: example of Na-proxen Na multi-centre Italian trial. In: Crescioni C, James JM, editors. Postmarketing clinical trials - the phase V studies. Paris: Editions de Sante; 1984. pp. 89–105.
31.
Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. Journal of Clinical Epidemiology. 1993;46(11):1323–1330. [PubMed: 8229110]
32.
Dangoumau J, Evreux JC, Jouglard J. Method for determination of undesirable effects of drugs. Therapie. 1978;33:373–381. [PubMed: 684688]
33.
Department of Health. NHS reference costs 2011-2012. 2013. [1 August 2013]. Available from: https://www​.gov.uk/government​/publications​/nhs-reference-costs-financial-year-2011-to-2012.
34.
Doeglas HM. Reactions to aspirin and food additives in patients with chronic urticaria, including the physical urticarias. British Journal of Dermatology. 1975;93(2):135–144. [PubMed: 1100092]
35.
Domingo MV, Marchuet MJC, Culla MTD, Joanpere RS, Guadano EM. Meloxicam tolerance in hypersensitivity to nonsteroidal anti-inflammatory drugs. Journal of Investigational Allergology and Clinical Immunology. 2006;16(6):364–366. [PubMed: 17153884]
36.
Dona I, Blanca-Lopez N, Cornejo-Garcia JA, Torres MJ, Laguna JJ, Fernandez J, et al. Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. Clinical and Experimental Allergy. 2011;41(1):86–95. [PubMed: 21155908]
37.
Dona I, Blanca-Lopez N, Jagemann LR, Torres MJ, Rondon C, Campo P, et al. Allergy. Malaga, Spain: Allergy Service, Carlos Haya Hospital; 2011. Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs. pp. 1428–1433. [PubMed: 21834936]
38.
Du W, Lehr VT, Lieh-Lai M, Koo W, Ward RM, Rieder MJ, et al. An algorithm to detect adverse drug reactions in the neonatal intensive care unit. Journal of Clinical Pharmacology. 2013;53(1):87–95. [PubMed: 23400748]
39.
El Miedany Y, Youssef S, Ahmed I, El Gaafary M. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. Annals of Allergy, Asthma and Immunology. 2006;97(1):105–109. [PubMed: 16892790]
40.
Emanueli A, Sacchetti G. An algorithm for the classification of untoward events in large scale clinical trials. Agents and Actions Supplements. 1980;7:318–322. [PubMed: 6941682]
41.
Eneh O, Fahy S. Audit of documentation of allergies in a psychiatric inpatient unit. Irish Journal of Psychological Medicine. 2011;28(4):213–216. [PubMed: 30200010]
42.
Evans RS, Classen DC, Pestotnik SL, Clemmer TP, Weaver LK, Burke JP. A decision support tool for antibiotic therapy. Proceedings of the Annual Symposium on Computer Application in Medical Care Symposium on Computer Applications in Medical Care. 1995:651–655.
43.
Evans RS, Pestotnik SL, Classen DC, Clemmer TP, Weaver LK, Orme JF Jr, et al. A computer-assisted management program for antibiotics and other antiinfective agents. New England Journal of Medicine. 1998;338(4):232–238. [PubMed: 9435330]
44.
Evans RS, Pestotnik SL, Classen DC, Horn SD, Bass SB, Burke JP. Preventing adverse drug events in hospitalized patients. Annals of Pharmacotherapy. 1994;28(4):523–527. [PubMed: 8038479]
45.
Evreux JC, Loupi E, Descotes J, Ventre JJ. [Evaluation of the documentation on adverse effects of drugs. Proposition. 2. Imputability]. Therapie. 1982;37(6):657–670. [PubMed: 7167869]
46.
Fisher M, Baldo BA. Anaphylaxis during anaesthesia: current aspects of diagnosis and prevention. European Journal of Anaesthesiology. 1994;11(4):263–284. [PubMed: 7925333]
47.
Fisher MM, Baldo BA. The incidence and clinical features of anaphylactic reactions during anesthesia in Australia. Annales Francaises D'Anesthesie Et De Reanimation. 1993;12(2):97–104. [PubMed: 8368592]
48.
Fisher MM, Baldo BA. Immunoassays in the diagnosis of anaphylaxis to neuromuscular blocking drugs: the value of morphine for the detection of IgE antibodies in allergic subjects. Anaesthesia and Intensive Care. 2000;28(2):167–170. [PubMed: 10788968]
49.
Fontaine C, Mayorga C, Bousquet PJ, Arnoux B, Torres MJ, Blanca M, et al. Relevance of the determination of serum-specific IgE antibodies in the diagnosis of immediate beta-lactam allergy. Allergy. 2007;62(1):47–52. [PubMed: 17156341]
50.
Franic DM, Pathak DS. Communicating the frequency of adverse drug reactions to female patients. Drug Information Journal. 2000;34(1):251–272.
51.
Frigas E, Park MA, Narr BJ, Volcheck GW, Danielson DR, Markus PJ, et al. Preoperative evaluation of patients with history of allergy to penicillin: comparison of 2 models of practice. Mayo Clinic Proceedings Mayo Clinic. 2008;83(6):651–662. [PubMed: 18533082]
52.
Gallagher RM, Kirkham JJ, Mason JR, Bird KA, Williamson PR, Nunn AJ, et al. Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. PloS One. 2011;6(12):e28096. [PMC free article: PMC3237416] [PubMed: 22194808]
53.
Garcia-Rodriguez RM, Hinojosa M, Camacho-Garrido E, Berges-Gimeno MP, Martin-Garcia C. Celecoxib, safe in NSAID intolerance. Allergy. 2002;57(11):1085–1086. [PubMed: 12359017]
54.
Garvey LH, Kroigaard M, Poulsen LK, Skov PS, Mosbech H, Venemalm L, et al. IgE-mediated allergy to chlorhexidine. Journal of Allergy and Clinical Immunology. 2007;120(2):409–415. [PubMed: 17559915]
55.
Goksel O, Aydin O, Misirligil Z, Demirel YS, Bavbek S. Safety of meloxicam in patients with aspirin/non-steroidal anti-inflammatory drug-induced urticaria and angioedema. Journal of Dermatology. 2010;37(11):973–979. [PubMed: 21039786]
56.
Gonzalez J, Guerra F, Moreno C, Miguel R, Daza JC, Sanchez Guijo P. Assessment of a self-designed protocol on patients with adverse reactions to beta-lactam antibiotics. Allergologia Et Immunopathologia. 1992;20(5):184–189. [PubMed: 1292326]
57.
Gyllfors P, Bochenek G, Overholt J, Drupka D, Kumlin M, Sheller J, et al. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. Journal of Allergy and Clinical Immunology. 2003;111(5):1116–1121. [PubMed: 12743579]
58.
Hackl WO, Ammenwerth E, Marcilly R, Chazard E, Luyckx M, Leurs P, et al. Clinical evaluation of the ADE scorecards as a decision support tool for adverse drug event analysis and medication safety management. British Journal of Clinical Pharmacology. 2013;76(S1):78–90. [PMC free article: PMC3781682] [PubMed: 24007454]
59.
Harboe T, Guttormsen AB, Irgens A, Dybendal T, Florvaag E. Anaphylaxis during anesthesia in Norway: a 6-year single-center follow-up study. Anesthesiology. 2005;102(5):897–903. [PubMed: 15851874]
60.
Harris MF, Giles A, O'Toole BI. Communication across the divide. A trial of structured communication between general practice and emergency departments. Australian Family Physician. 2002;31(2):197–200. [PubMed: 11917836]
61.
Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. International Journal of Epidemiology. 1999;28(4):717–722. [PubMed: 10480701]
62.
Hippern LD, Halapy H. Assessing penicillin allergies with a structured assessment form. Canadian Journal of Hospital Pharmacy. 2000;53(3):184–192.
63.
Holm A, Mosbech H. Challenge test results in patients with suspected penicillin allergy, but no specific iGE. Allergy. 2011;3(2):118–122. [PMC free article: PMC3062790] [PubMed: 21461251]
64.
Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Annals of Pharmacotherapy. 2007;41(4):674–680. [PubMed: 17389673]
65.
Hoskins W, Mannino S. Causality assessment of adverse drug reactions using decision support and infomatics tools. Pharmacoepidemiology and Drug Safety. 1992;1992(1):235.
66.
Hsieh TC, Kuperman GJ, Jaggi T, Hojnowski-Diaz P, Fiskio J, Williams DH, et al. Characteristics and consequences of drug allergy alert overrides in a computerized physician order entry system. Journal of the American Medical Informatics Association. 2004;11(6):482–491. [PMC free article: PMC524628] [PubMed: 15298998]
67.
Hsu PH, Stoll RW. Causality assessment of adverse events in clinical trials: II. An algorithm for drug causality assessment. Drug Information Journal. 1993;27(2):387–394.
68.
Hughes L, Whittlesea C, Luscombe D. Patients' knowledge and perceptions of the side-effects of OTC medication. Journal of Clinical Pharmacy and Therapeutics. 2002;27(4):243–248. [PubMed: 12174025]
69.
Hunteman L, Ward L, Read D, Jolly M, Heckman M. Analysis of allergy alerts within a computerized prescriber-order-entry system. American Journal of Health-System Pharmacy. 2009;66(4):373–377. [PubMed: 19202047]
70.
Hutchinson TA. Computerised Bayesian ADE assessment. Drug Information Journal. 1991;25(2):235–241.
71.
Immunology Quality Services. Protein reference units. 2013. [19 November 2013]. Available from: http://www​.immqas.org.uk/pru.asp?ID=316.
72.
Inomata N, Osuna H, Yamaguchi J, Onoda M, Takeshita Y, Chiba Y, et al. Safety of selective cyclooxygenase-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID-induced urticaria and/or angioedema: Comparison of meloxicam, etodolac and tiaramide. Journal of Dermatology. 2007;34(3):172–177. [PubMed: 17291297]
73.
Irey NS. Teaching monograph. Tissue reactions to drugs. American Journal of Pathology. 1976;82(3):613–647. [PMC free article: PMC2032418] [PubMed: 1258979]
74.
Joint Formulary Committee. British National Formulary (BNF). 67th edition. London: British Medical Association and The Royal Pharmaceutical Society of Great Britain; 2014. Available from: http://www​.bnf.org.
75.
Jones JK. Adverse drug reactions in the community health setting: approaches to recognizing, counseling, and reporting. Family and Community Health. 1982;5(2):58–67. [PubMed: 10278126]
76.
Kane-Gill SL, Forsberg EA, Verrico MM, Handler SM. Comparison of three pharmacovigilance algorithms in the ICU setting: a retrospective and prospective evaluation of ADRs. Drug Safety. 2012;35(8):645–653. [PubMed: 22720659]
77.
Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clinical Pharmacology and Therapeutics. 1977;21(3):247–254. [PubMed: 837643]
78.
Kasper L, Sladek K, Duplaga M, Bochenek G, Liebhart J, Gladysz U, et al. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy. 2003;58(10):1064–1066. [PubMed: 14510727]
79.
Kerr JR. Penicillin allergy: a study of incidence as reported by patients. British Journal of Clinical Practice. 1994;48(1):5–7. [PubMed: 8179985]
80.
Kitaguchi T, Nohiri T, Suzuki S. Some assesment systems for industry post marketing adverse drug reaction (ADR) information. Iyakuhin Kenkyu. 1983;14:980–982.
81.
Kleinhans M, Linzbach L, Zedlitz S, Kaufmann R, Boehncke WH. Positive patch test reactions to celecoxib may be due to irritation and do not correlate with the results of oral provocation. Contact Dermatitis. 2002;47(2):100–102. [PubMed: 12423408]
82.
Koh Y, Shu CL. A new algorithm to identify the causality of adverse drug reactions. Drug Safety. 2005;28(12):1159–1161. [PubMed: 16329718]
83.
Koschel D, Ninck Weber C, Hoffken G. Tolerability to etoricoxib in patients with aspirin-exacerbated respiratory disease. Journal of Investigational Allergology and Clinical Immunology. 2013;23(4):275–280. [PubMed: 23964558]
84.
Kraft D, Roth A, Mischer P, Pichler H, Ebner H. Specific and total serum IgE measurements in the diagnosis of penicillin allergy. A long term follow-up study. Clinical Allergy. 1977;7(1):21–28. [PubMed: 406099]
85.
Kraft D, Wide L. Clinical patterns and results of radioallergosorbent test (RAST) and skin tests in penicillin allergy. British Journal of Dermatology. 1976;94(6):593–601. [PubMed: 779818]
86.
Kramer MS, Hutchinson TA. The Yale algorithm. Special workshop--clinical. Drug Information Journal. 1984;18(3-4):283–291. [PubMed: 10268557]
87.
Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA. 1979;242(7):623–632. [PubMed: 449002]
88.
Krska J, Anderson C, Murphy E, Avery AJ. How patient reporters identify adverse drug reactions: a qualitative study of reporting via the UK Yellow Card Scheme. Drug Safety. 2011;34(5):429–436. [PubMed: 21513365]
89.
Kuperman GJ, Gandhi TK, Bates DW. Effective drug-allergy checking: methodological and operational issues. Journal of Biomedical Informatics. 2003;36(1-2):70–79. [PubMed: 14552848]
90.
Laaksonen R, Duggan C, Bates I. Desire for information about drugs: relationships with patients' characteristics and adverse effects. Pharmacy World and Science. 2002;24(5):205–210. [PubMed: 12426966]
91.
Lagier G, Vincens M, Castot A. [Imputability in drug monitoring. Principles of the balanced drug reaction assessment method and principal errors to avoid]. Therapie. 1983;38(3):303–318. [PubMed: 6612667]
92.
Lanctot KL, Kwok MCO, Naranjo CA. Computerised Bayesian evaluation of adverse events. Drug Information Journal. 1995;29:319–325.
93.
Lanctot KL, Naranjo CA. Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. Clinical Pharmacology and Therapeutics. 1995;58(6):692–698. [PubMed: 8529335]
94.
Lane DA, Kramer MS, Hutchinson TA, Jones JK, Naranjo C. The causality assessment of adverse drug reactions using a Bayesian approach. Pharmaceutical Medicine. 1987;2(3):265–283.
95.
Laroche D, Chollet-Martin S, Leturgie P, Malzac L, Vergnaud MC, Neukirch C, et al. Evaluation of a new routine diagnostic test for immunoglobulin e sensitization to neuromuscular blocking agents. Anesthesiology. 2011;114(1):91–97. [PubMed: 21169794]
96.
Lee CE, Zembower TR, Fotis MA, Postelnick MJ, Greenberger PA, Peterson LR, et al. The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance. Archives of Internal Medicine. 2000;160(18):2819–2822. [PubMed: 11025792]
97.
Leung AA, Schiff G, Keohane C, Amato M, Simon SR, Cadet B, et al. Impact of vendor computerized physician order entry on patients with renal impairment in community hospitals. Journal of Hospital Medicine. 2013;8(10):545–552. [PubMed: 24101539]
98.
Liccardi G, Cazzola M, De Giglio C, Manfredi D, Piscitelli E, D'Amato M, et al. Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and other non-steroidal anti-inflammatory drugs. Journal of Investigational Allergology and Clinical Immunology. 2005;15(4):249–253. [PubMed: 16433205]
99.
Liccardi G, Salzillo A, Piccolo A, Senna GE, Piscitelli E, D'Amato M, et al. Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs. European Annals of Allergy and Clinical Immunology. 2005;37(2):50–53. [PubMed: 15859361]
100.
Llanora GV, Loo EXL, Gerez IF, Cheng YK. Etoricoxib: a safe alternative for NSAID intolerance in Asian patients. Asian Pacific Journal of Allergy and Immunology. 2013;31(4):330–333. [PubMed: 24383977]
101.
Lorimer S, Cox A, Langford NJ. A patient's perspective: the impact of adverse drug reactions on patients and their views on reporting. Journal of Clinical Pharmacy and Therapeutics. 2012;37(2):148–152. [PubMed: 21592157]
102.
Macy EM, Contreras R. Journal of Allergy and Clinical Immunology. 2. Vol. 133. Elsevier; 2014. Healthcare Utilization and Serious Infection Prevalence Associated With Penicillin “Allergy” In Hospitalized Patients: A Cohort Study; p. AB153. [PubMed: 24188976]
103.
Mahoney CD, Berard-Collins CM, Coleman R, Amaral JF, Cotter CM. Effects of an integrated clinical information system on medication safety in a multi-hospital setting. American Journal of Health-System Pharmacy. 2007;64(18):1969–1977. [PubMed: 17823111]
104.
Malinovsky JM, Decagny S, Wessel F, Guilloux L, Mertes PM. Systematic follow-up increases incidence of anaphylaxis during adverse reactions in anesthetized patients. Acta Anaesthesiologica Scandinavica. 2008;52(2):175–181. [PubMed: 18005384]
105.
Marco AP, Buchman D, Lancz C. Influence of form structure on the anesthesia preoperative evaluation. Journal of Clinical Anesthesia. 2003;15(6):411–417. [PubMed: 14652116]
106.
Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 1997;26:664–669. [PubMed: 9303497]
107.
Martin-Garcia C, Hinojosa M, Berges P, Camacho E, Garcia-Rodriguez R, Alfaya T. Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients. Journal of Investigational Allergology and Clinical Immunology. 2003;13(1):20–25. [PubMed: 12861847]
108.
Martinez JA, Ruthazer R, Hansjosten K, Barefoot L, Snydman DR. Role of environmental contamination as a risk factor for acquisition of vancomycin-resistant enterococci in patients treated in a medical intensive care unit. Arch Intern Med. 2003;163(16):1905–1912. [PubMed: 12963563]
109.
Mashford ML. The Australian method of drug-event assessment. Special workshop--regulatory. Drug Information Journal. 1984;18(3-4):271–273. [PubMed: 10268555]
110.
Mead GE, Cunnington AL, Faulkner S, Russell KJ, Ford MJ. Can general practitioner referral letters for acute medical admissions be improved? Health Bulletin. 1999;57(4):257–261. [PubMed: 12811886]
111.
Menendez MD, Alonso J, Rancano I, Corte JJ, Herranz V, Vazquez F. Impact of computerized physician order entry on medication errors. Revista De Calidad Asistencial. 2012;27(6):334–340. [PubMed: 22465826]
112.
Mertes PM, Laxenaire MC, Alla F., Groupe d'Etudes des Reactions Anaphylactoides Peranesthesiques. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000. Anesthesiology. 2003;99(3):536–545. [PubMed: 12960536]
113.
Michel DJ, Knodel LC. Comparison of three algorithms used to evaluate adverse drug reactions. American Journal of Hospital Pharmacy. 1986;43(7):1709–1714. [PubMed: 3752106]
114.
Mihaela TA, Popescu FD, Mariana V, Florica P. The safety profile of etoricoxib in autoreactive urticaria. Therapeutics, Pharmacology and Clinical Toxicology. 2012;16(2):116–120.
115.
Mirakian R, Ewan PW, Durham SR, Youlten LJ, Dugue P, Friedmann PS, et al. BSACI guidelines for the management of drug allergy. Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology. 2009;39(1):43–61. [PubMed: 19128352]
116.
Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Archives of Internal Medicine. 2007;167(16):1752–1759. [PubMed: 17846394]
117.
Moore-Robinson M, Warin RP. Effect of salicylates in urticaria. British Medical Journal. 1967;4(5574):262–264. [PMC free article: PMC1748904] [PubMed: 6054001]
118.
Mullett CJ, Evans RS, Christenson JC, Dean JM. Development and impact of a computerized pediatric antiinfective decision support program. Pediatrics. 2001;108(4):E75. [PubMed: 11581483]
119.
Muratore L, Ventura M, Calogiuri G, Calcagnile F, Quarta E, Muratore M, et al. Annals of Allergy, Asthma & Immunology: Official Publication of the American College of Allergy, Asthma, & Immunology. Lecce, Italy: Allergology and Clinical Immunology Service, Vito Fazzi Hospital; 2007. Tolerance to etoricoxib in 37 patients with urticaria and angioedema induced by nonsteroidal anti-inflammatory drugs. pp. 168–171. [PubMed: 17304885]
120.
Naccarelli GV, Panaccio MP, Cummins G, Tu N. CHADS2 and CHA2DS2-VASc risk factors to predict first cardiovascular hospitalization among atrial fibrillation/atrial flutter patients. American Journal of Cardiology. 2012;109(10):1526–1533. [PubMed: 22360819]
121.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapeutics. 1981;30(2):239–245. [PubMed: 7249508]
122.
National Clinical Guideline Centre. Patient experience in adult NHS services: improving the experience of care for people using adult NHS services. NICE clinical guideline 138. London: National Clinical Guideline Centre; 2012. Available from: http://www​.nice.org.uk/CG138.
123.
National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance. 2nd edition. London: National Institute for Health and Clinical Excellence; 2008. Available from: http://www​.nice.org.uk​/media/C18/30/SVJ2PUBLICATION2008.pdf. [PubMed: 27905706]
124.
National Institute for Health and Clinical Excellence. Anaphylaxis: assessment to confirm an anaphylactic episode and the decision to refer after emergency treatment for a suspected anaphylactic episode. NICE clinical guideline 134. London: National Institute for Health and Clinical Excellence; 2011. Available from: http://guidance​.nice.org.uk/CG134. [PubMed: 25340233]
125.
National Institute for Health and Clinical Excellence. The guidelines manual. London: National Institute for Health and Clinical Excellence; 2012. Available from: http://publications​.nice​.org.uk/the-guidelines-manual-pmg6/ [PubMed: 27905714]
126.
National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal 2013. 2nd Ed edition. London: National Institute for Health and Clinical Excellence; 2013. Available from: http://publications​.nice.org.uk/pmg9. [PubMed: 27905712]
127.
Nettis E, Di Paola R, Ferrannini A, Tursi A. Meloxicam in hypersensitivity to NSAIDs. Allergy. 2001;56(8):803–804. [PubMed: 11488693]
128.
Nettis E, Colanardi MC, Ferrannini A, Vacca A, Tursi A. Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Annals of Allergy, Asthma and Immunology. 2005;95(5):438–442. [PubMed: 16312166]
129.
Neubert A, Dormann H, Prokosch HU, Burkle T, Rascher W, Sojer R, et al. E-pharmacovigilance: development and implementation of a computable knowledge base to identify adverse drug reactions. British Journal of Clinical Pharmacology. 2013;76(Suppl 1):69–77. [PMC free article: PMC3781681] [PubMed: 23586589]
130.
NHS England. Drug allergies: an eight year review of NRLS medication incident reports 01 April 2005 to 31 March 2013. 2013. (unpublished)
131.
Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP). 2013. [16 January 2013]. Available from: http://www​.oecd.org/std/ppp.
132.
Ortega A, Aguinagalde A, Lacasa C, Aquerreta I, Fernandez-Benitez M, Fernandez LM. Efficacy of an adverse drug reaction electronic reporting system integrated into a hospital information system. Annals of Pharmacotherapy. 2008;42(10):1491–1496. [PubMed: 18780808]
133.
Pagani M, Bonadonna P, Dama A, Senna GE, Vescovi PP, Antico A. Long-term tolerability of etoricoxib in different types of NSAID-intolerant subjects. European Annals of Allergy and Clinical Immunology. 2010;42(6):216–220. [PubMed: 21287945]
134.
Pere JC, Begaud B, Haramburu F, Albin H. Computerized comparison of six adverse drug reaction assessment procedures. Clinical Pharmacology and Therapeutics. 1986;40(4):451–461. [PubMed: 3757408]
135.
Porter SC, Manzi SF, Volpe D, Stack AM. Getting the data right: information accuracy in pediatric emergency medicine. Quality and Safety in Health Care. 2006;15(4):296–301. [PMC free article: PMC2564018] [PubMed: 16885256]
136.
Prieto A, De Barrio M, Martin E, Fernandez-Bohorquez M, de Castro FJ, Ruiz FJ, et al. Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance. Journal of Allergy and Clinical Immunology. 2007;119(4):960–964. [PubMed: 17292954]
137.
Qiao HL, Liu JH, Yang J, Dong ZM. Relationships between skin test, specific IgE and levels of cytokines in patients with penicillin allergy. International Journal of Clinical Practice. 2005;59(8):895–899. [PubMed: 16033609]
138.
Quaratino D, Romano A, Di Fonso M, Papa G, Perrone MR, D'Ambrosio FP, et al. Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs. Annals of Allergy, Asthma and Immunology. 2000;84(6):613–617. [PubMed: 10875490]
139.
Quiralte J, Delgado J, Saenz de San Pedro B, Lopez-Pascual E, Nieto MA, Ortega N, et al. Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. Annals of Allergy, Asthma and Immunology. 2004;93(4):360–364. [PubMed: 15521372]
140.
Roll A, Wuthrich B, Schmid-Grendelmeier P, Hofbauer G, Ballmer-Weber BK. Tolerance to celecoxib in patients with a history of adverse reactions to nonsteroidal anti-inflammatory drugs. Swiss Medical Weekly. 2006;136(43-44):684–690. [PubMed: 17183430]
141.
Sala-Cunill A, Cardona V, Labrador-Horrillo M, Luengo O, Esteso O, Garriga T, et al. Usefulness and limitations of sequential serum tryptase for the diagnosis of anaphylaxis in 102 patients. International Archives of Allergy and Immunology. 2013;160(2):192–199. [PubMed: 23018683]
142.
Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Cutaneous hypersensitivity reactions to inhibitors of cyclooxygenase-2 - Results from 307 oral provocation tests and review of the literature. Allergy and Clinical Immunology International. 2007;19(2):44–49.
143.
Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F, Perez CR. Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Annals of Allergy, Asthma and Immunology. 2001;87(3):201–204. [PubMed: 11570615]
144.
Sanz ML, Gamboa PM, De Weck AL. Clinical evaluation of in vitro tests in diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy and Clinical Immunology International. 2002;14(5):185–193.
145.
Sanz ML, Garcia BE, Prieto I, Tabar A, Oehling A. Specific IgE determination in the diagnosis of beta-lactam allergy. Journal of Investigational Allergology and Clinical Immunology. 1996;6(2):89–93. [PubMed: 8727264]
146.
Sard BE, Walsh KE, Doros G, Hannon M, Moschetti W, Bauchner H. Retrospective evaluation of a computerized physician order entry adaptation to prevent prescribing errors in a pediatric emergency department. Pediatrics. 2008;122(4):782–787. [PMC free article: PMC4136972] [PubMed: 18829802]
147.
Schadow G. Structured product labeling improves detection of drug-intolerance issues. Journal of the American Medical Informatics Association. 2009;16(2):211–219. [PMC free article: PMC2649322] [PubMed: 18952933]
148.
Senna G, Bilo MB, Antonicelli L, Schiappoli M, Crivellaro MA, Bonadonna P, et al. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. European Annals of Allergy and Clinical Immunology. 2004;36(6):215–218. [PubMed: 15329003]
149.
Senna GE, Passalacqua G, Dama A, Crivellaro M, Schiappoli M, Bonadonna P, et al. Nimesulide and meloxicam are a safe alternative drugs for patients intolerant to nonsteroidal anti-inflammatory drugs. European Annals of Allergy and Clinical Immunology. 2003;35(10):393–396. [PubMed: 14768525]
150.
Silva R, Cruz L, Botelho C, Cadinha S, Castro E, Rodrigues J, et al. Work up of patients with history of beta-lactam hypersensitivity. Allergologia Et Immunopathologia. 2009;37(4):193–197. [PubMed: 19775797]
151.
Silva R, Cruz L, Botelho C, Castro E, Cadinha S, Castel-Branco MG, et al. Immediate hypersensitivity to penicillins with negative skin tests - The value of specific IgE. European Annals of Allergy and Clinical Immunology. 2009;41(4):117–119. [PubMed: 19877564]
152.
Simmonds M, Petterson J. Anaesthetists' records of pre-operative assessment. British Journal of Clinical Governance. 2000;5(1):22–27. [PubMed: 11183964]
153.
Soller RW, Shaheen C, Yen J, Rose J, Lightwood J. Improvement of the Drug Allergy Alert for Nonprescription NSAIDs. Drug Information Journal. 2012;46(3):336–343.
154.
Son YM, Lee JR, Roh JY. Causality assessment of cutaneous adverse drug reactions. Annals of Dermatology. 2011;23(4):432–438. [PMC free article: PMC3229935] [PubMed: 22148009]
155.
Soto CM, Kleinman KP, Simon SR. Quality and correlates of medical record documentation in the ambulatorycare setting. BMC Health Services Research. 2002;2:1–7. [PMC free article: PMC140026] [PubMed: 12473161]
156.
Spina JR, Glassman PA, Simon B, Lanto A, Lee M, Cunningham F, et al. Potential safety gaps in order entry and automated drug alerts: a nationwide survey of VA physician self-reported practices with computerized order entry. Medical Care. 2011;49(10):904–910. [PubMed: 21666510]
157.
Stephens MD. Assesment of causality in industrial settings. special workshop - industrial. Drug Information Journal. 1984;18:307–313.
158.
Stricker BHC. Diagnosis and causality assessment of drug-induced hepatic injury. In: Dukes MNG, editor. Drug-induced hepatic injury. Amsterdam: Elsevier; 1985. pp. 1–13.
159.
Tamblyn R, Huang A, Taylor L, Kawasumi Y, Bartlett G, Grad R, et al. A randomized trial of the effectiveness of on-demand versus computer-triggered drug decision support in primary care. Journal of the American Medical Informatics Association. 2008;15(4):430–438. [PMC free article: PMC2442270] [PubMed: 18436904]
160.
Theophile H, Andre M, Miremont-Salame G, Arimone Y, Begaud B. Comparison of three methods (an updated logistic probabilistic method, the naranjo and liverpool algorithms) for the evaluation of routine pharmacovigilance case reports using consensual expert judgement as reference. Drug Safety. 2013;36(10):1033–1044. [PubMed: 23828659]
161.
Trewin VF. The design of an algorithm for pharmacists to evaluate ADRs in the elderly. Journal of Clinical Pharmacy and Therapeutics. 1991;16(1):45–53. [PubMed: 2026668]
162.
Turner WM. The Food and Drug Administration algorithm. Special workshop--regulatory. Drug Information Journal. 1984;18(3-4):259–266. [PubMed: 10268553]
163.
University of Bristol. QUADAS-2. 2011. [18 February 2014]. Available from: http://www​.bris.ac.uk/quadas/quadas-2/
164.
Valero A, Sanchez-Lopez J, Bartra J, Serrano C, Munoz-Cano R, Roca J, et al. Safety of parecoxib in asthmatic patients with aspirin-exacerbated respiratory disease. International Archives of Allergy and Immunology. 2011;156(2):221–223. [PubMed: 21597303]
165.
Varkey P, Aponte P, Swanton C, Fischer D, Johnson SF, Brennan MD. The effect of computerized physician-order entry on outpatient prescription errors. Managed Care Interface. 2007;20(3):53–57. [PubMed: 17458483]
166.
Vega JM, Blanca M, Garcia JJ, Carmona MJ, Miranda A, Perez-Estrada M, et al. Immediate allergic reactions to amoxicillin. Allergy. 1994;49(5):317–322. [PubMed: 8092427]
167.
Venulet J, Ciucci A, Berneker GC. Standardized assessment of drug-adverse reaction associations-rationale and experience. International Journal of Clinical Pharmacology, Therapy, and Toxicology. 1980;18(9):381–388. [PubMed: 7450930]
168.
Viola M, Quaratino D, Gaeta F, Caringi M, Valluzzi R, Caruso C, et al. Celecoxib tolerability in patients with hypersensitivity (mainly cutaneous reactions) to nonsteroidal anti-inflammatory drugs. International Archives of Allergy and Immunology. 2005;137(2):145–150. [PubMed: 15897671]
169.
Viola M, Quaratino D, Gaeta F, Caruso C, Valluzzi R, Romano A. Etoricoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs. International Archives of Allergy and Immunology. 2007;143(2):103–108. [PubMed: 17228166]
170.
Vultaggio A, Matucci A, Virgili G, Rossi O, Fili L, Parronchi P, et al. Influence of total serum IgE levels on the in vitro detection of beta-lactams-specific IgE antibodies. Clinical and Experimental Allergy. 2009;39(6):838–844. [PubMed: 19400911]
171.
Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine. 2011;155(8):529–536. [PubMed: 22007046]
172.
Woessner KM, Simon RA, Stevenson DD. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis and Rheumatism. 2002;46(8):2201–2206. [PubMed: 12209526]
173.
Wolfstadt JI, Gurwitz JH, Field TS, Lee M, Kalkar S, Wu W, et al. The effect of computerized physician order entry with clinical decision support on the rates of adverse drug events: a systematic review. Journal of General Internal Medicine. 2008;23(4):451–458. [PMC free article: PMC2359507] [PubMed: 18373144]
174.
World Health Organisation UMC. The use of the WHO_UMC system for standardised case causality assessment. 2007. Available from: http://who-umc​.org/Graphics/24734.pdf.
175.
Zenk KE, Randall RJ, Fukumitsu CJ. Notation of allergies and body weight on patient profiles. Drug Intelligence and Clinical Pharmacy. 1984;18(7-8):625–626. [PubMed: 6745091]